Literature DB >> 7578992

Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.

K Warzocha1, J Bienvenu, B Coiffier, G Salles.   

Abstract

In the past few years, a number of experimental observations have provided more insight into the mechanisms of action of tumor necrosis factor (TNF)/lymphotoxin (LT) ligand-receptor system. This system consists of three ligands, TNF, LT alpha (LT alpha) and LT beta (LT beta), and three membrane-associated receptors, p55, p75 and LT beta-receptor (LT beta-R). Like TNF, LT alpha is a secreted protein which in solution forms a homotrimer molecule, with a conformation similar to that of TNF. LT beta is a transmembrane protein that provides the membrane anchor for the attachment to the cell surface of the heteromeric complex of LT alpha and LT beta. This complex retains a structure related to TNF and LT alpha homotrimers, with the homology regions interacting in a heterotypic fashion. The LT alpha 1:LT beta 2 heteromer has been found to be a predominant form of surface LT. The biological effects of TNF and LT alpha homotrimers are mediated by p55 and p75 receptors, while the heteromeric complex of LT alpha/LT beta transduces its cellular signal via LT beta-R. Membrane-associated receptor affinities as well as final biological effects of TNF/LT can be modulated by the influence of naturally occurring soluble receptors, derived from the cell surface by proteolytic cleavage. The multimerization of receptor cytoplasmic domains upon TNF/LT ligation is postulated to activate the intracellular signal-transduction pathways. One of them is the activation of phospholipase A2 (PL-A2) resulting in the production of arachidonic acid (AA) and other metabolites, including leukotriens, phosphatidycholine-specific phospholipase C (PC-PLC) with subsequent production of diacylglycerol (DAG) and activation of protein kinase C (PKC). As a third signaling pathway, TNF/LT employ the sphingomyelinase (SMase)-mediated hydrolysis of membrane sphingomyelin (SM) to ceramide. The final link in the TNF/LT signaling is activation of nuclear transcription factors, such as NF-kappa B, AP-1, interferon regulatory factors-1 and -2 (IRF-1, IRF-2), and NF-GMa. Since induction of AP-1, IRF-1 and IRF-2 as well as NF-GMa proceeds through translational event, the posttranslational TNF/LT-driven activation of NF-kappa B remains the only cellular event identified so far that serves as a direct target in their signaling cascade.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578992

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  11 in total

Review 1.  Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.

Authors:  J Kempeni
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 2.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

Review 3.  Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries.

Authors:  Antonella Montinaro; Henning Walczak
Journal:  Cell Death Differ       Date:  2022-10-04       Impact factor: 12.067

4.  Enhanced Anti-Cancer Effects of Conditioned Medium from Hypoxic Human Adult Dermal Fibroblasts on Cervical Cancer Cells.

Authors:  Kyu-Hyun Han; Ae-Kyeong Kim; Dong-Ik Kim
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

5.  Host cell signalling and leishmania mechanisms of evasion.

Authors:  Marina Tiemi Shio; Kasra Hassani; Amandine Isnard; Benjamin Ralph; Irazu Contreras; Maria Adelaida Gomez; Issa Abu-Dayyeh; Martin Olivier
Journal:  J Trop Med       Date:  2011-11-03

Review 6.  The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.

Authors:  Anand Kumar Gupta; Sonali Das; Mohd Kamran; Sarfaraz Ahmad Ejazi; Nahid Ali
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

7.  The safety of etanercept for the treatment of plaque psoriasis.

Authors:  Kim A Papp
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

8.  Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy.

Authors:  Martin Stanulla; André Schrauder; Karl Welte; Martin Schrappe
Journal:  BMC Blood Disord       Date:  2001

Review 9.  The Cross-Talk Between the TNF-α and RASSF-Hippo Signalling Pathways.

Authors:  Delvac Oceandy; Bella Amanda; Faisal Yusuf Ashari; Zakiyatul Faizah; M Aminudin Azis; Nicholas Stafford
Journal:  Int J Mol Sci       Date:  2019-05-11       Impact factor: 5.923

10.  Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients.

Authors:  K Warzocha; J Bienvenu; P Ribeiro; I Moullet; C Dumontet; E M Neidhardt-Berard; B Coiffier; G Salles
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.